Genomic Analysis of Pediatric Bone Tumors

Completed

• Conditions: Bone Cancer

• Registration Number: NCT01047878
• Lead Sponsor: Stanford University

Brief Summary

To determine whether gene expression analysis of primary tumor samples before and after chemotherapy are predictive of long-term survival in pediatric patients with bone sarcomas (Ewings sarcoma (ES) and Osteosarcoma(OS)).

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2007-08
• Study First Submitted: 2010-01-11
• Study First Submitted QC: 2010-01-12
• Study First Posted: 2010-01-13
• Primary Completion: 2018-06
• Study Completion: 2019-12
• Status Verified: 2020-07
• Last Update Submitted: 2020-07-24
• Last Update Posted: 2020-07-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 163

Inclusion Criteria

All patients with bone x-rays suggestive of a malignant bone tumor

Read More

Exclusion Criteria

Patients with a known diagnosis of cancer.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
% necrosis post chemotherapy	his is measured at the time of sample collection since we are looking for % necrosis in the sample we are collecting
overall survival and event free survival	This is measured at the time the patient dies, or at the time when patient relapses from their disease. There is no set time since this outcome is individually assessed.

Trial Locations

Locations (1)

Stanford University School of Medicine; 🇺🇸 Stanford, California, United States